Functional Neuroimaging in Depression

Phase 2CompletedNCT00343070

University Hospital, Ghent40 enrolled

Overview

Oral administration of escitalopram during 8 weeks; PET scan with 18F-FDG at inclusion and after 8 weeks

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Major Depression

Interventions

Oral administration of escitalopram during 8 weeksDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Major Depression, Depressive episode, following DSM-IV criteria * MADRS-score \> 25 * Age: 18-65 yrs * Medication-free or anti-depressant wash-out 7 days (for fluoxetine: 6 weeks) * Lorazepam 1mg or zolpidem 10mg are allowed Exclusion Criteria: * Suicidality * Bipolar disorder, following DSM-IV criteria * Psychotic symptoms * Substance abuse * Personality disorder, following DSM-IV criteria * Cognitive dysfunction due to trauma capitis or dementia * Diabetes mellitus * Women without contraceptive protection, with pregnancy or breast feeding * Pharmacological treatment or ingestion of substance that can influence cerebral perfusion less than a month before inclusion * IQ below 80 * Conditions not compatible with SPC

Locations (2)

University Hospital Ghent

Ghent, Belgium

AZ Groeninge campus Sint Maarten

Kortrijk, Belgium

Outcomes

Primary Outcomes

Brain metabolism

Secondary Outcomes

Cognitive functions

Efficacy scales (mood, anxiety, anger and hopelessness)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.